KMS Medisurgi Ltd

As of August 8, 2025, KMS Medisurgi is considered overvalued with a PE ratio of 41.75 and an EV to EBITDA of 41.87, but it has outperformed the Sensex with a 269.34% return over three years, making it relatively more attractive than peers like Poly Medicure and Blue Jet Health.

As of August 8, 2025, KMS Medisurgi is considered overvalued with a valuation grade of risky, reflected by a PE ratio of 41.75, an EV to EBIT of 41.87, and a ROE of 5.74%, while its year-to-date return of 1.2% lags behind the Sensex's 2.20%.

As of August 8, 2025, KMS Medisurgi is considered overvalued with a risky valuation grade, reflected by high financial ratios compared to its peers, despite strong return performance over the past few years.

As of July 23, 2025, KMS Medisurgi is considered very expensive and overvalued, with a high PE ratio of 39.77 and a year-to-date return of -3.6%, indicating it trades at a premium compared to its peers and has no growth expectations.

The top shareholders of KMS Medisurgi are Moni Diamonds Limited with 19.21% and Yagnesh Manaharlal Joshi as the highest public shareholder at 5.82%. Individual investors hold a total of 21.7%, with no mutual fund or foreign institutional investor holdings and no pledged promoter shares.

KMS Medisurgi's peers include Aspira Pathlab, Amkay Products, N G Industries, Bandaram Pharma, Deccan Healthcar, Medinova Diagno., Tejnaksh Health., GKB Ophthalmics, and Transgene Biotek. In terms of performance, Aspira Pathlab leads with a 1-year return of 64.58%, while KMS Medisurgi has a return of 0.80%.

As of June 27, 2025, KMS Medisurgi is considered very expensive with a PE ratio of 41.91 and other high valuation metrics, indicating it is overvalued compared to its peers and the industry, despite having delivered strong returns in the past.

As of June 27, 2025, KMS Medisurgi is considered very expensive with a PE ratio of 41.91, significantly overvalued compared to peers like Poly Medicure and Vimta Labs, and has underperformed the Sensex with a year-to-date return of only 1.6%.

As of June 27, 2025, KMS Medisurgi is considered very expensive and overvalued, with a PE ratio of 41.91 and lower return metrics, underperforming the Sensex with a return of only 1.6% compared to 6.08%.

As of April 15, 2024, KMS Medisurgi's technical trend is neutral, with the price stagnant at 125.00 and no significant movement in the 52-week high or low.

As of April 15, 2024, KMS Medisurgi's technical trend is neutral, with the price stagnant at 125.00 and no significant movement in the 52-week high or low.

As of April 16, 2024, KMS Medisurgi is considered risky and overvalued with a PE ratio of 41.25, significantly higher than its healthcare peers, despite a strong three-year stock return of 266.57% compared to the Sensex's 49.16%.

As of Apr 05, KMS Medisurgi Ltd has a market capitalization of 40.00 Cr, classifying it as a Micro Cap company, with shareholder's funds of 7.66 Cr and total assets of 10.73 Cr; however, no recent financial data is available for the latest four quarters.

As of March 2022, the management team of KMS Medisurgi includes Rekha Devang Kanakia (Chairman & Managing Director), Kamlesh Chunilal Rajani, Hardik Rajnikant Bhatt, Pratik Pravin Tarpara (all Independent Directors), Sidddharth Kanakia, Rohan Devang Kanakia (Directors), and Sunny Gupta (Company Secretary & Compliance Officer). Each member contributes to the company's governance and strategic direction.

KMS Medisurgi Ltd is a micro-cap healthcare services company that manufactures and coats substrates with adhesive. It was incorporated in 1999 and became a public company in 2016, with a market cap of Rs 40 Cr.

As of 05-Jun, KMS Medisurgi Ltd is priced at Rs 125.00, showing no change today. The stock has reached a new all-time high and is trading above all key moving averages, indicating strong performance despite a flat week and month compared to the benchmark Sensex.